ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S

Alzheimer's disease is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. The treatment will allow people to have more time to participate in daily life and live independently two treatments — donanemab (Kisunla™) and lecanemab (Leqembi®) — demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer's. Other treatments can temporarily slow the worsening of dementia symptoms and improve quality of life for those with living Alzheimer's and their caregivers. Today, there is a worldwide effort underway to find better ways to treat the disease, delay its onset and prevent it from developing. is critical to ensure that the person living with dementia receives the best possible care. They work differently by targeting beta-amyloid at different stages of plaque formation, and ultimately these treatments lower beta-amyloid to slow progression of the disease and to reduce clinical decline.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-09-15
DOI
https://doi.org/10.5281/zenodo.17258402
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S

Zenodo (CERN European Organization for Nuclear Research)
Cancer Immunotherapy and Biomarkers
article

ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S

article en

Abstract

Alzheimer's disease is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. The treatment will allow people to have more time to participate in daily life and live independently two treatments — donanemab (Kisunla™) and lecanemab (Leqembi®) — demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer's. Other treatments can temporarily slow the worsening of dementia symptoms and improve quality of life for those with living Alzheimer's and their caregivers. Today, there is a worldwide effort underway to find better ways to treat the disease, delay its onset and prevent it from developing. is critical to ensure that the person living with dementia receives the best possible care. They work differently by targeting beta-amyloid at different stages of plaque formation, and ultimately these treatments lower beta-amyloid to slow progression of the disease and to reduce clinical decline.

Zenodo (CERN European Organization for Nuclear Research)
Batumi Shota Rustaveli State University (GE)
Openalex Percentile: Top 37%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS